Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Piccirillo

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
British Journal of Cancer|April 6, 2013
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trialG Nasti, M C Piccirillo, F Izzo, et al.
ESMO Open|March 7, 2024
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trialsL Arenare, R Di Liello, P De Placido, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2016
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in ItalyF Perrone, C Jommi, M Di Maio, et al.
Cancer Biology & Therapy|July 27, 2010
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trialGaetano Facchini, Michele Caraglia, Alessandro Morabito, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
JAMA Network Open|July 26, 2021
Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical TrialAntonio Avallone, Maria C Piccirillo, Guglielmo Nasti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
ESMO Open|January 5, 2023
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II studyC Cardone, A De Stefano, G Rosati, et al.
ESMO Open|January 4, 2025
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patientsA Gravina, P Gargiulo, M De Laurentiis, et al.
Journal of Cancer Policy|October 6, 2025
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patientsL Arenare, C Porta, D Barberio, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|April 6, 2013
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trialG Nasti, M C Piccirillo, F Izzo, et al.
ESMO Open|March 7, 2024
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trialsL Arenare, R Di Liello, P De Placido, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2016
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in ItalyF Perrone, C Jommi, M Di Maio, et al.
Cancer Biology & Therapy|July 27, 2010
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trialGaetano Facchini, Michele Caraglia, Alessandro Morabito, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
JAMA Network Open|July 26, 2021
Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical TrialAntonio Avallone, Maria C Piccirillo, Guglielmo Nasti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
ESMO Open|January 5, 2023
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II studyC Cardone, A De Stefano, G Rosati, et al.
ESMO Open|January 4, 2025
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patientsA Gravina, P Gargiulo, M De Laurentiis, et al.
Journal of Cancer Policy|October 6, 2025
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patientsL Arenare, C Porta, D Barberio, et al.
Pageof 4